Merus N.V.

MRUS

$4.00B

Mid Cap

NASDAQPharmaceutical Preparations🇺🇸North America3584 CM UTRECHT260 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 15, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

1 upcoming, 0 past

Phase 2Next

MCLA-129 Phase 2 Results Expected

March 2026~MCLA-129576

Primary completion for MCLA-129 trial (NCT04868877) in Non-Small Cell Lung Cancer Metastatic

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Petosemtamab

Phase 3

Head and Neck Squamous Cell Carcinoma

Investigator's Choice

Phase 3

Head and Neck Squamous Cell Carcinoma

MCLA-158

Phase 2

Advanced/Metastatic Solid Tumors

Zenocutuzumab

Phase 2

Breast Cancer Metastatic

MCLA-129

Phase 2

Non-Small Cell Lung Cancer Metastatic

Drug Name	Phase	Indication	Designations
Petosemtamab	Phase 3	Head and Neck Squamous Cell Carcinoma	-
Investigator's Choice	Phase 3	Head and Neck Squamous Cell Carcinoma	-
MCLA-158	Phase 2	Advanced/Metastatic Solid Tumors	-
Zenocutuzumab	Phase 2	Breast Cancer Metastatic	-
MCLA-129	Phase 2	Non-Small Cell Lung Cancer Metastatic	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

MRUS News